143
Participants
Start Date
June 29, 2018
Primary Completion Date
July 31, 2026
Study Completion Date
May 31, 2027
zolbetuximab
Zolbetuximab will be administered as a minimum 2-hour IV infusion.
oxaliplatin
Oxaliplatin will be administered as a 2-hour IV infusion.
leucovorin
Leucovorin will be administered as a 2-hour IV infusion.
fluorouracil
Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.
Pembrolizumab
Pembrolizumab will be administered intravenously over 30 minutes.
folinic acid
Folnic acid will be administered as a 2-hour IV infusion.
nivolumab
Nivolumab will be administered intravenously according to institutional standards.
Docetaxel
Docetaxel will be administered as a 1-hour IV infusion.
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medical College, New York
Site FR33003, Pessac
University of Chicago, Chicago
Site TW88602, Tainan City
Site FR33004, Paris
Site FR33002, Poitiers
The Angeles Clinic and Research Institute, Los Angeles
UCLA Medical Center, Santa Monica
Mass General / North Shore Can, Boston
Site FR33001, Brest
Site IT39005, Milan
Site IT39002, Napoli
Site IT39004, Padua
Site IT39003, Pisa
Site JP81001, Chiba
Site JP81002, Tokyo
Site JP81003, Tokyo
Site KR82002, Seongnam-si
Site KR82001, Seoul
Site TW88601, Taichung
Astellas Pharma Global Development, Inc.
INDUSTRY